Progress in the Design of Molecular Targeted Drugs for Gastric Cancer

Yuxi Wang

doi:10.54097/ijbls.v4i1.08

Authors

Yuxi Wang

DOI:

https://doi.org/10.54097/ijbls.v4i1.08

Keywords:

Molecular Targeted Drug, Trastuzumab Apatinib, Gastric Cancer Treatment

Abstract

Gastric cancer is one of the most common cancers in China, and its pathogenesis is related to many molecular signaling pathways and related factors. The more critical molecular pathways include MET pathway, PI3K / AKT pathway, and MAPK pathway. In addition, the EGFR family and factors related to tumor angiogenesis are also important factors, which are closely related to tumor cell proliferation, apoptosis, and metastasis. The results of the study will provide new ideas and methods for the treatment of gastric cancer and lay the groundwork for the development of new gastric cancer drugs. On this basis, a variety of molecular targeted drugs have entered the clinical trial stage, among which, trastuzumab and apatinib have shown good efficacy. This paper summarizes the molecular pathogenesis of gastric cancer, and summarizes the mechanism of action, combination chemotherapy and research progress of trastuzumab and apatinib, so as to provide reference for future research on targeted therapy for gastric cancer.

Downloads

Download data is not yet available.

References

TAKAHASHI T, SAIKAWA Y, KITAGAWA Y. (2013) Gastric cancer: current status of diagnosis and treatment. Cancers (Basel), 5(1): 48-63.

ALI S M, SANFORD E M, KLEMPNER S J, et al. (2015) Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist, 20(5): 499-507.

HSIEH A C, MOASSER M M. (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer, 97(4): 453-7.

KAKEJI Y, KOGA T, SUMIYOSHI Y, et al. (2002) Clinical significance of vascular endothelial growth factor expression in gastric cancer. Journal of Experimental & Clinical Cancer Research: CR, 21(1): 125-9.

OKINES A, CUNNINGHAM D, CHAU I. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology, 8(8): 492-503.

BANG Y-J, VAN CUTSEM E, FEYEREISLOVA A, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376(9742): 687-97.

LIETO E, FERRARACCIO F, ORDITURA M, et al. (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Annals of Surgical Oncology, 15:69-79.

ZHANG Y, GOU M, HAN C, et al.(2018) Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: A single-center observational study. Anti-Cancer Drugs, 29(2): 184-9.